Loading clinical trials...
Loading clinical trials...
This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis treated with tegaserod over 2 weeks.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis
NCT05398783 · Metabolic Disorders, Cancer, and more
NCT07224321 · Type 1 Diabetes Mellitus
NCT07395050 · Stage 3 Type 1 Diabetes
NCT01399385 · Healthy, Obesity, and more
NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
The University of Kansas Medical Center
Kansas City, Kansas
The University of Louisville
Louisville, Kentucky
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions